Targeting Staphylococci in Atopic Dermatitis

Atopic Dermatitis Clinical Trial

Official title:

Targeting Staphylococci Adhesion and Colonization on the Surface of Corneocytes in Atopic Dermatitis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05502185
• Other study ID #: ACR_TCDUB_22-11995
• Status: Not yet recruiting
• Start date: September 1, 2022
• Est. completion date: September 1, 2023

Study information

• Verified date: August 2022
• Source: L'Oreal
• Contact: AUDREY GUENICHE, pHD
• Phone: 0660992467
• Email: audrey.gueniche[@]rd.loreal.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of the study is to deliver a better understanding of the molecular mechanisms used by S. epidermidis strains in their adhesion and colonization on the stratum corneum across a broad spectrum of atopic dermatitis in mild to moderate conditions in adult patients.

Description:

Recent studies have shown that while in severe cases of AD the density of S. aureus is increased in lesions, the skin of adult patients with low to mild AD were overpopulated with S. epidermidis and not S. aureus.

the aim is to characterize the S. epidermidis colonization and adhesion, with the Analyzis of skin and microbiota samples to identify and characterize S. epidermidis strains involved in corneocytes adhesion.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: September 1, 2023
• Est. primary completion date: September 1, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• • Male/Female subject from 18 years old or above.

• Subject willing and able to fulfil the study requirements and schedule

• Subject informed about the study objectives and procedures, and able to understand them

• Subject who has given written informed consent

• Subject with I, II, III or IV skin phototype

• Specific criteria:

For AD patients:

• Subject diagnosed with AD (via UK working party criteria) with a mild-to-moderate severity defined as EASI<32 and vIGA between 2 and 3

• Subject with at least one AD lesion covering at least 4 cm²

For healthy volunteers:

• Subject matching the demographic characteristics of a patient included in the AD group:

same sex, same phototype, same age (± 5 years)

Exclusion Criteria:

• Subject with a body mass index (BMI) higher than 40

• Presenting another dermatological condition that could interfere with the clinical evaluation

• Presenting any concomitant medical condition that may interfere with the study conduct in the opinion of the investigator

• Topical or systemic treatment that could interfere with the study treatment/assessments (topical benzoyl peroxide, salicylic acid and other anti-acne or antiseborrheic products, antibiotics, corticosteroids, retinoids, differin gel, retin-A, anti-inflammatory drugs, within the 4 weeks prior to the participation in the study.

• Any physical treatment including laser or phototherapy (PUVA, IPL, PDT), topical fillers such as Botox on the investigational sites in the last 6 months and during the study

• Subject treated with systemic non-steroidal anti-inflammatory drugs (=3 days) within 1 week before the inclusion visit or intending to be treated with it during the study.

• Subject treated with biological immunosuppressive drugs within 12 weeks prior to the inclusion visit or intending to be treated with it during the study.

• Subject treated with non-biological immunosuppressive drugs within 4 weeks prior to the inclusion visit or intending to be treated with it during the study.

• Subject treated with systemic corticoids within 1 week prior to the inclusion visit or planed during the study.

• Subject treated with systemic antibiotics within 2 weeks prior to the inclusion visit or planned during the study.

• Subject having applied topical corticosteroids and topical calcineurin inhibitors on the investigational areas within 1 week prior to the inclusion visit.

• Subject having applied topical immunomodulators, non-steroidal anti-inflammatory, antihistamines on investigational area within 1 week prior to the inclusion visit.

• Subject having applied topical antibiotics or disinfectants on investigational area within 2 weeks prior to the inclusion visit.

• Subject having applied any other topical and/or care product within 12 hours of the visit.

• Subject having applied water or care product (except hands cleaning) within 12 hours prior to the inclusion visit.

• Subject having significant dermatological condition or sign (e.g disease, scare, abundant hairiness, tanning mark…) that according to the investigator's judgment, could limit the observations or/and interfere with the interpretations.

• Subject having performed phototherapy within 8 weeks prior to the inclusion visit or intending to perform phototherapy during the study.

• Subject having performed another physical treatment (e.g radiotherapy…) on the investigational areas within 6 months prior to the inclusion visit or intending to perform it during the study.

• Subject having exposed their skin to natural or artificial UV within 2 weeks prior to the inclusion visit

• Subject under legal guardianship or incapacitation.

• Subject who declares to be deprived of freedom by administrative or legal decision

• Subject linguistically or psychologically unable of signing informed consent form and unable to comply with the protocol requirements according to the investigator's judgment.

• Subject who cannot be contacted by telephone in case of emergency.

• Subject having participated within the 30 days before inclusion or currently participating in another clinical study.

Related Conditions & MeSH terms

• Atopic Dermatitis
• Dermatitis
• Dermatitis, Atopic
• Eczema

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
L'Oreal

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Identification of S. epidermidis adhesins	Identification of S. epidermidis adhesins involved in corneocytes adhesion, in mild-to moderate AD conditions	1 week
Secondary	characterization of corneocytes	characterization of corneocytes morphology from clinical sourcing of lesional and non lesional zones of AD subjects, mild-to-moderate and healthy volunteers, and characterization of the interaction between S. epidermidis adhesins and AD corneocytes	1 week